AbCellera Biologics Inc.
ABCL
$3.85
$0.071.85%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 38.03M | 50.39M | 145.18M | 181.04M | 485.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.03M | 50.39M | 145.18M | 181.04M | 485.43M |
| Cost of Revenue | 31.78M | 73.28M | 76.98M | 72.41M | 90.76M |
| Gross Profit | 6.24M | -22.89M | 68.19M | 108.63M | 394.66M |
| SG&A Expenses | 75.18M | 71.81M | 70.85M | 69.02M | 66.76M |
| Depreciation & Amortization | 24.40M | 22.28M | 21.69M | 20.97M | 19.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.23M | 250.92M | 253.08M | 245.95M | 260.52M |
| Operating Income | -237.21M | -200.53M | -107.91M | -64.91M | 224.91M |
| Income Before Tax | -174.03M | -156.84M | -70.98M | -39.86M | 239.10M |
| Income Tax Expenses | -27.63M | -27.70M | 2.93M | 10.31M | 80.58M |
| Earnings from Continuing Operations | -146.40 | -129.14 | -73.91 | -50.16 | 158.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.40M | -129.14M | -73.91M | -50.16M | 158.52M |
| EBIT | -237.21M | -200.53M | -107.91M | -64.91M | 224.91M |
| EBITDA | -212.81M | -178.29M | -86.23M | -43.95M | 244.35M |
| EPS Basic | -0.51 | -0.45 | -0.26 | -0.17 | 0.56 |
| Normalized Basic EPS | -0.39 | -0.33 | -0.13 | -0.07 | 0.55 |
| EPS Diluted | -0.52 | -0.45 | -0.27 | -0.19 | 0.49 |
| Normalized Diluted EPS | -0.39 | -0.33 | -0.14 | -0.08 | 0.50 |
| Average Basic Shares Outstanding | 1.16B | 1.15B | 1.15B | 1.14B | 1.14B |
| Average Diluted Shares Outstanding | 1.16B | 1.15B | 1.18B | 1.17B | 1.20B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
